CSII - CSII STOCK NEWS

Cardiovascular Systems, Inc. (CSII) reported significant financial results for Q4 fiscal 2021, with revenues of $71.0 million, a 66.8% increase year-over-year. The U.S. peripheral and coronary franchises saw sequential revenue growth of double digits. Total revenues for fiscal 2021 reached $259.0 million, a 9.5% growth from the previous year. Despite a net loss of $5.3 million for Q4, it was an improvement compared to last year’s net loss. Looking ahead, CSII forecasts 2022 revenues between $295 million and $305 million, indicating a 14% to 18% growth.

Cardiovascular Systems, Inc. (NASDAQ: CSII) announced plans to attend three key investor conferences in August 2021, focusing on interventional treatment systems for vascular diseases. The conferences include the Guggenheim MedTech Disruptors Summit on August 10, the Canaccord Genuity 41^st Annual Growth Conference on August 11 at 12:30 p.m. ET (with a Webcast) and the 6^th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 17.

Cardiovascular Systems, Inc. (NASDAQ: CSII) will hold a live webcast for its fiscal 2021 fourth-quarter conference call on August 4, 2021, at 3:30 p.m. CT to discuss results for the quarter ending June 30, 2021. A post-market earnings release will precede the call. The company specializes in innovative medical devices for vascular and coronary diseases, including an orbital atherectomy system designed to treat calcified plaques in arterial vessels.

Cardiovascular Systems, Inc. (NASDAQ: CSII) has announced its participation in the Raymond James Human Health Innovations Conference on June 23, 2021, where management will conduct investor meetings. The event is scheduled for 10:40 a.m. ET, and a webcast will be available on CSI's website. The company specializes in innovative medical devices for treating vascular and coronary diseases, notably its orbital atherectomy system that addresses limitations in current treatment methods. For more details, visit www.csi360.com.

Cardiovascular Systems, Inc. (NASDAQ: CSII) announced the U.S. launch of the complete line of OrbusNeich JADE PTA over-the-wire balloon catheters, expanding their distribution of innovative medical devices. The JADE catheters, designed for high pressure tolerance and even inflation, are used for treating peripheral artery disease, a condition affecting over 18 million Americans. The successful adoption by leading physicians indicates strong potential for meaningful revenue growth in CSI's peripheral product portfolio.

Cardiovascular Systems, Inc. (NASDAQ: CSII) announced results from a real-world study presented at EuroPCR 2021, focusing on the efficacy of the Diamondback 360^® Coronary Orbital Atherectomy System (OAS) in treating severely calcified coronary lesions. The study involved 20 patients, all of whom experienced 100% lesion treatment success and showed no complications. The findings highlighted the effectiveness of the OAS in facilitating stent delivery and improving patient outcomes, indicating a potential shift in coronary intervention practices.

Cardiovascular Systems, Inc. (CSII) reported a 3.4% increase in fiscal Q3 revenues, reaching $63.3 million, driven by strong coronary franchise performance. The gross profit margin stood at 77.9%, but the company faced a net loss of $6.0 million, worsening from a $2.9 million loss year-over-year. Anticipating Q4 revenues of $67-$70 million, CSII's margins will temporarily dip due to production adjustments and a one-time charge. The company is optimistic about market recovery and plans to launch peripheral support devices soon, aiming for enhanced procedure volumes.

Cardiovascular Systems, Inc. (NASDAQ: CSII) announced a new study published in the Journal of Medical Economics detailing the two-year costs of healthcare for patients with Peripheral Artery Disease (PAD) who participated in the LIBERTY 360° trial. The study revealed notable cost differences based on initial treatment methods. Key findings indicate high rates of freedom from major amputation across various patient categories, particularly with orbital atherectomy, which demonstrated lower cumulative costs compared to traditional methods. The mean two-year PAD-related costs were reported at $29,474 for orbital atherectomy versus $30,491 for all patients.

Cardiovascular Systems, Inc. (NASDAQ: CSII) is set to host investor meetings at the BofA Securities 2021 Health Care Conference on May 11, 2021, at 5:00 p.m. ET. The conference will feature a presentation by management, with a webcast available on CSI's website.

CSI focuses on innovative interventional treatments for vascular and coronary disease, utilizing an orbital atherectomy system to address calcified plaque in arterial vessels.